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Abstract: Parkinson’s disease (PD) is a progressive, chronic, neurodegenerative disease 
characterized by rigidity, tremor, bradykinesia and postural instability secondary to dopaminergic 
deficit in the nigrostriatal system. Currently, disease-modifying therapies are not available, and 
levodopa (LD) treatment remains the gold standard for controlling motor and nonmotor symp-
toms of the disease. LD is extensively and rapidly metabolized by peripheral enzymes, namely, 
aromatic amino acid decarboxylase and catechol-O-methyltransferase (COMT). To increase the 
bioavailability of LD, COMT inhibitors are frequently used in clinical settings. Opicapone is a 
novel COMT inhibitor that has been recently approved by the European Medicines Agency as 
an adjunctive therapy to combinations of LD and aromatic amino acid decarboxylase inhibitor 
in adult PD patients with end-of-dose motor fluctuations. We aimed to review the biochemi-
cal properties of opicapone, summarize its preclinical and clinical trials and discuss its future 
potential role in the treatment of PD.
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Introduction
Parkinson’s disease (PD) is a progressive, chronic, neurodegenerative disease 
characterized by rigidity, tremor, bradykinesia and postural instability secondary 
to dopaminergic deficit in the nigrostriatal system.1–3 Currently, disease-modifying 
therapies are not available, and levodopa (LD) treatment remains the gold standard 
for controlling motor symptoms of the disease.4–7 Nonmotor symptoms (eg, cognitive 
decline, psychiatric symptoms, autonomic and sleep disturbance, etc) also cause a 
marked decrease in the quality of life, but currently there is limited evidence that LD 
treatment can alleviate these symptoms. Furthermore, within 5 years of treatment, ~50% 
of patients develop motor fluctuations and dyskinesia.1,2,8 The pathophysiology behind 
motor complications is that instead of physiologic, tonic stimulation, there is a reduced 
and pulsatile dopaminergic stimulation of striatal neurons.9 This is due to fluctuations 
in the plasma concentration of LD and progressive neuronal cell death in the nigros-
triatal system.10 Therefore, the aim of improving treatment is to provide a steadier and 
more sustained plasma concentration of LD and consequent continuous dopaminergic 
transmission in the basal ganglia.
LD is the precursor of dopamine (DA), and unlike DA, it can penetrate through 
the blood–brain barrier (BBB). However, after oral intake, LD is extensively and 
rapidly metabolized by peripheral enzymes, namely, aromatic amino acid decar-
boxylase (AADC) and catechol-O-methyltransferase (COMT). Figure 1 shows 
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the peripheral and intraneural metabolism of LD. COMT 
catalyzes the transfer of a methyl group from S-adenosyl 
methionine (SAM) to catechol estrogens and endogenous 
catecholamines.11 After the transfer, the co-substrate 
becomes S-adenosyl homocysteine (SAHcy). The catalytic 
cycle is complete when SAHcy is exchanged to SAM and 
COMT can catalyze another O-methylation. In the central 
nervous system (CNS), LD is broken down to homova-
nillic acid (HVA) by COMT and monoamine oxidase 
(MAO). When LD is administered alone, approximately 
only 1% of the oral dose reaches the CNS.12–14 When LD 
is administered with an AADC inhibitor (benserazide 
[BZ] or carbidopa [CD]), ~90% of LD is converted to 
3-O-methyldopa (3-OMD) by COMT, which could compete 
with LD for transport through the BBB.15–17 The clinical 
significance of 3-OMD as a competitive antagonist to LD 
is questionable.16,17 3-OMD is considered as a biomarker 
of peripheral COMT inhibition.18 Currently, there are three 
COMT inhibitors that can be used in the treatment of PD, 
entacapone (ENT), tolcapone (TCP), and since its approval 
for medical use by the European Medicines Agency in 
June 2016, opicapone (OPC; Ongentys®, developed by 
Bial-Portela & Ca. S.A.).19,20 OPC is indicated as an adjunc-
tive therapy to combinations of LD/DOPA decarboxylase 
inhibitors (DDCIs) in adult PD patients with end-of-dose 
motor fluctuations whose symptoms cannot be stabilized 
with these preparations. Peripheral COMT inhibitors, like 
OPC, increase the half-life of LD, whereas central inhibitors 
slow its metabolism within the CNS.9 Our review high-
lights the biochemical properties of OPC and summarizes 
preclinical investigations and clinical trials with this novel 
COMT inhibitor.
Pharmacokinetic and 
pharmacodynamic properties 
of OPC
OPC (2,5-dichloro-3-[5-(3,4-dihydroxy-5-nitrophenyl]-1,2-
4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide, previously 
known as BIA 9-1067) is a novel third-generation nitrocat-
echol COMT inhibitor that has been approved for medical 
use by the European Medicines Agency in June 2016.20,21 
Figure 2 shows the chemical structure of OPC. It is indicated 
as an adjunctive therapy to combinations of LD/DDCI in 
adult PD patients with end-of-dose motor fluctuations whose 
symptoms cannot be stabilized with these combinations. OPC 
has a pyridine N-oxide residue at position 3, providing high-
affinity COMT inhibition and avoidance of cell toxicity.22 
OPC has a very high protein-binding affinity in the plasma 
(.99%).23 Kiss et al22 found that OPC does not cross the BBB 
in rats and monkeys. An in vitro study using parallel artificial 
membrane permeability assay (PAMPA) also confirmed 
that OPC does not penetrate into the brain.24 Consequently, 
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Figure 1 LD metabolism and place of action of OPC.
Abbreviations: 3-MT, 3-methoxy-tyramine; 3-OMD, 3-O-methyldopa; AADC, aromatic amino acid decarboxylase; BBB, blood–brain barrier; COMT, catechol-O-
methyltransferase; DA, dopamine; DOPAC, 3,4-dihydroxy-phenylacetic acid; HvA, homovanillic acid; LD, levodopa; MAO, monoamine oxidase; OPC, opicapone.
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it was concluded that OPC inhibits only peripheral COMT 
enzymes. COMT is present in all mammalian tissues and has 
been shown to have the highest activity in the liver, kidney 
and cells of the gastrointestinal tract.25 Human erythrocytes 
also contain COMT and are generally used in clinical trials 
for the assessment of COMT activity. OPC has a remarkably 
high-affinity binding to COMT (dissociation constant is in 
the subpicomolar range).26 In comparison, the same constant 
is two magnitudes higher for TCP.
Almeida et al27 found that after a single oral administra-
tion of various doses (10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 
400 mg, 800 mg and 1,200 mg) of OPC to healthy subjects, 
the terminal half-life ranged between 0.8 h (for 50 mg) 
and 3.2 h (for 1,200 mg). LD was given concomitantly and 
maximum LD concentration was detected between 1.5 h 
and 3.5 h. The maximum COMT inhibition was dose depen-
dent and ranged between 36.1% (10 mg OPC) and 100% 
(200 mg–1,200 mg OPC). The inhibitory effect reached its 
peak between 0.7 h and 6.2 h post-dose.27 After 24 h of intake, 
OPC exerted COMT inhibitory effect ranging from 26.1% 
(10 mg) to 76.5% (800 mg). At 72 h post-dose, OPC still 
had COMT inhibitory effect: 5.9% (10 mg OPC) to 54.6% 
(800 mg).27 Systemic exposure to OPC was significantly 
lower after a high-fat, high-calorie meal compared to after 
fasting, implying that OPC should be taken before meals. 
The only metabolite detected in the urine of participants 
was BIA 9-1106.
Despite its relatively quick elimination from the circula-
tion, OPC has a sustained COMT inhibitory effect. Rocha 
et al28 hypothesized that the long-lasting effect of OPC 
might be related to its binding to the complex of COMT–
SAHcy, thus blocking the exchange of SAM to SAHcy 
and therefore hindering the O-methylation of another OPC 
molecule.
In nonclinical studies, the following five metabolites of 
OPC have been detected: BIA 9-1100 and BIA 9-1101 are 
inactive methylated metabolites, BIA 9-1103 is an inactive 
sulfated metabolite, BIA 9-1106 is an inactive glucuronide 
metabolite and BIA 9-1079 is an active COMT-inhibitor 
metabolite.27,28 OPC is mainly metabolized by sulfation to 
BIA 9-1103. Reduction to BIA 9-1079 and glucuronidation 
to BIA 9-1106 are alternate metabolic routes.27,28 A total 
of 70% of orally administered radiolabeled 14C-OPC was 
eliminated by feces in human beings,23 whereas 12% of the 
drug was excreted by urine. Therefore, hepatobiliary excre-
tion seems to be the main elimination pathway for OPC. 
In patients with moderate liver impairment (Child-Pugh 
category B, scores 7–9), compared to healthy controls, 
increased the bioavailability of OPC was detected, possibly 
due to decreased first-pass effect in the liver. No serious 
adverse events or treatment-related adverse events were 
found in either groups.23
Pinto et al29 have demonstrated that neither 50 mg nor 
800 mg of OPC caused clinically significant changes in 
electrocardiogram (ECG) morphology and intervals. A study 
was conducted where healthy white and Japanese subjects 
were given 5 mg, 25 mg and 50 mg OPC or placebo (PLC).30 
No statistically significant differences were found in the 
pharmacokinetics and pharmacodynamics of OPC between 
the two populations.
Animal studies with OPC
In one study, OPC was given orally to rats and resulted in sig-
nificant reduction in COMT activity.31 The maximum plasma 
concentration was detected at 4 h following administration. 
OPC could not be detected after 8 h post-admission. When 
LD/BZ was given to rats 2 h and 24 h after administration of 
OPC, the maximum plasma concentration of LD increased 
by 1.6- and 1.4-fold, bioavailability of LD increased by 1.9- 
and 1.3-fold and 3-OMD exposure decreased by 6.3- and 
1.6-fold, respectively.31 In the same study, adenosine triphos-
phate (ATP) concentrations and mitochondrial membrane 
potentials were measured after 24 h of incubation of human 
primary hepatocytes to investigate cytotoxic properties. 
Compared to TCP and ENT, OPC was the least potent 
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Figure 2 Chemical structure of OPC (2,5-dichloro-3-[5-(3,4-dihydroxy-5-
nitrophenyl]-1,2-4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide).
Abbreviation: OPC, opicapone.
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compound to decrease mitochondrial membrane potential 
and ATP content of hepatocytes.31
In brain and liver homogenates of rats, OPC caused a 
more sustained COMT inhibitory effect compared to ENT 
and TCP.32 The medications were administered through a 
gastric tube 1 h after intake, and COMT inhibition reached 
99%, 82% and 68%, respectively, with OPC, TCP and 
ENT. After 9 h of administration, OPC still showed a 91% 
reduction in COMT activity. No inhibitory effects of ENT 
could be detected and TCP produced only a 16% decrease 
in COMT activity.32
Bonifácio et al33 examined systemic and central bioavail-
ability of LD and its metabolites in cynomolgus monkeys. 
Microdialysis probes were inserted into the substantia 
nigra, dorsal striatum and prefrontal cortex of monkeys. 
The animals received either vehicle or 100 mg/kg OPC for 
14 days, and then they were challenged with a combination 
of LD and BZ (12/3 mg/kg). Blood samples and extracellular 
dialyzate from the brain were collected for measurements. 
Compared to PLC, a significant increase in LD levels was 
observed in the plasma and also in the dialyzate samples 
obtained from all three brain regions (1.7-, 1.4- and 2.3-fold 
increase in dorsal striatum, substantia nigra and prefrontal 
cortex, respectively).33 In addition, reduced 3-OMD exposure 
was observed (fivefold decrease in plasma and fivefold, sev-
enfold and 2.4-fold decrease in the dorsal striatum, substantia 
nigra and prefrontal cortex, respectively). Furthermore, 
erythrocyte COMT activity in the plasma decreased by 
~76%–84%.33
Clinical trials in healthy subjects
Almeida et al investigated the pharmacokinetic and phar-
macodynamic properties and tolerability of OPC after a 
single oral administration of various doses (10 mg, 25 mg, 
50 mg, 100 mg, 200 mg, 400 mg, 800 mg and 1,200 mg).27 
Systemic exposure to OPC and its metabolites showed an 
approximately dose-dependent pattern. Human erythrocyte 
COMT inhibition was also dose dependent. The half-life of 
COMT inhibition was 61.6 h. Detailed results of the trial are 
discussed in the second paragraph of the “Pharmacokinetic 
and pharmacodynamic properties of OPC” section of this 
article.
In a dose-escalation, double-blind, PLC-controlled study, 
healthy male subjects were given 5 mg, 10 mg, 20 mg or 
30 mg OPC for 8 days.28 The pharmacokinetic and phar-
macodynamic properties of OPC and its metabolites were 
investigated. The terminal half-life of OPC ranged from 1 h 
to 1.4 h. BIA 9-1103 was identified as the main metabolite. 
Its terminal half-life was between 25.1 h and 26.9 h. Although 
BIA 9-1079 is an active metabolite, it only represented ,20% 
of systemic exposure to OPC. Therefore, it only has minor 
relevance in the therapeutic effect of OPC.28 COMT inhibi-
tion was found to be dose dependent. The maximum inhi-
bition was detected between 3.8 h and 7.7 h after the first 
administration and 3.7 h and 5.3 h after the last intake of 
OPC. Long-lasting COMT inhibition was found. At 144 h 
after the last dose 16.3%, 21.3%, 31.4% and 20.3% decrease 
in COMT activity still remained with 5 mg, 10 mg, 20 mg 
and 30 mg OPC, respectively.28 Previously, the maximum 
COMT inhibition for 100 mg and 200 mg TCP and 200 mg 
ENT was found to be 72%, 80% and 65% respectively.34,35 
COMT activity returned to baseline within ~18 h and 8 h 
after TCP and ENT, respectively.
In another study, healthy individuals received 25 mg, 
50 mg, and 75 mg OPC or PLC for 11 days.36 On the 12th 
day, subjects in the PLC group received 200 mg ENT and 
LD/CD three times a day. Individuals in the OPC group 
were also administered LD and CD three times daily to 
assess the effects of OPC on LD pharmacokinetics. The 
minimum LD plasma concentration increased in all active 
treatment groups compared to the PLC arm (1.7- and 
3.3-fold with 200 mg ENT and 75 mg OPC, respectively). 
All active treatments resulted in increased LD bioavail-
ability and significant decrease in 3-OMD exposure in rela-
tion to the PLC group.36 Compared to ENT, OPC showed 
a more sustained effect on erythrocyte COMT inhibition. 
Adverse events were mild, the most common ones being 
nausea, vomiting, headache and dizziness. No serious 
adverse events were reported. It was concluded that OPC 
was more efficacious compared to ENT in increasing LD 
bioavailability.36
Table 1 summarizes the main findings of clinical trials 
in healthy subjects.
Clinical trials in PD patients
In a phase II study, patients diagnosed with idiopathic PD, 
who had at least 1.5 h long OFF state in the waking day 
and a modified Hoehn–Yahr stage of ,5 h in the OFF state, 
received 25 mg, 50 mg, and 100 mg OPC or PLC once daily 
in addition to their previous 100/25 mg LD and CD or BZ 
therapy.37 The maximum plasma concentration of LD dose 
dependently increased after OPC intake compared to PLC. 
A marked decrease was observed in peak 3-OMD levels and 
also in the extent of exposure with 100 mg OPC. All active 
treatments inhibited the extent and rate of COMT activity in 
a dose-dependent, albeit disproportional, manner.37 Motor 
responses were also measured. A marked decrease in time to 
ON and time to best ON was detected. ON duration increased 
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by 18% and 25% with 25 mg and 50 mg OPC, respectively. 
Adverse events were mostly mild to moderate in intensity.37
Ferreira et al38 investigated the effects of 28-day long 
administration of 5 mg, 15 mg and 30 mg OPC on LD 
pharmacokinetics, COMT inhibition and motor fluctuations 
in PD patients. The population of the study was similar to 
that described in the previous trial. All active treatments 
increased LD bioavailability in a dose-dependent manner, 
caused sustained dose-dependent but not proportional COMT 
inhibition and consequently a significantly lower exposure to 
3-OMD. Based on the participants’ diaries, all active treat-
ments caused a dose-dependent decrease in the absolute OFF 
time (15.6 min and 145 min with 5 mg and 30 mg OPC, 
respectively).38 Overall, 15 mg and 30 mg OPC reached 
statistical significance compared to PLC in improving ON 
time without dyskinesia. The investigators’ and patients’ 
global assessment of change was also favorable. No serious 
adverse events occurred during the study.38
BIPARK I was a phase III, randomized, double-blind, 
multicenter, PLC- and active-controlled trial that assessed 
the efficacy and safety profile of OPC.21 OPC was adminis-
tered as an adjunct therapy to LD in PD patients with motor 
fluctuations. Participants were aged between 30 years and 
83 years, had a clinical diagnosis of PD for at least 3 years, a 
Hoehn–Yahr stage of 1–3 during the ON state and had to have 
end-of-dose motor fluctuations for at least 4 weeks before 
screening. Initially, 600 patients met the inclusion criteria 
and were randomly assigned to five groups: patients either 
received PLC, 200 mg ENT or 5 mg, 25 mg, or 50 mg OPC 
for 14–15 weeks in addition to LD (administered three to 
eight times a day). OPC was given once daily and 1 h after 
the last LD dose. The primary end point was the change in 
the absolute time in the OFF state assessed by daily patient 
diaries.21 Key secondary end points included the change in 
the proportion of patients showing at least 1 h of reduction in 
the absolute time in the OFF state. Moreover, the proportion 
of patients achieving at least 1 h increase in the absolute time 
spent in the ON state was assessed. A significantly differ-
ent reduction in the OFF time was reported for 50 mg OPC 
compared to PLC (−116.8 min and −56 min, respectively). 
ENT also showed a statistically different reduction in the 
absolute time spent in the OFF state (−96.3 min).21 These 
findings were in accordance with previous studies.39 Based 
on these results, the authors concluded that 50 mg OPC was 
superior to PLC and non-inferior to ENT. The 5 mg and 
25 mg doses of OPC did not show significant reduction in 
the time spent in the OFF state compared to PLC. Regarding 
the secondary end points, a significantly higher proportion of 
patients showed at least 1 h reduction in the OFF state in the 
25 mg and 50 mg OPC groups compared to PLC. In addi-
tion, the proportion of patients who had at least 1 h increase 
in the ON state was significantly higher in the 50 mg OPC 
arm. In all, 190 patients had treatment-related adverse 
events in the OPC groups.21 Most common adverse events 
were dyskinesia (44 patients among those receiving OPC), 
insomnia (16 patients) and constipation (11 patients taking 
OPC). Altogether, nine patients had serious adverse event in 
the OPC groups, including one who had a marked increase 
in the level of liver enzymes but no hyperbilirubinemia. No 
fatal events were reported. Therefore, OPC was found to 
have a favorable safety profile.21
In the BIPARK II study (as of yet, data are available only 
as abstract), which was a multinational, PLC-controlled, 
double-blind, parallel-group study, 25 mg and 50 mg OPC 
Table 1 Summary of clinical trials in healthy subjects
References Design Main findings
Almeida et al27 Single oral administration of various 
doses of OPC (10 mg, 25 mg, 50 mg, 
100 mg, 200 mg, 400 mg, 800 mg and 
1,200 mg) with LD
•	 Terminal half-life of OPC: 0.8 h (50 mg) to 3.2 h (1,200 mg)
•	 Maximum LD concentration between 1.5 h and 3.5 h
•	 Maximum COMT inhibition between 36.1% (10 mg OPC) and 100%  
(200–1,200 mg OPC)
•	 72 h post-dose inhibitory effect: 5.9% (10 mg OPC) to 54.6% (800 mg OPC)
Rocha et al28 Male subjects received 5 mg, 10 mg, 
20 mg or 30 mg OPC for 8 days
•	 Terminal half-life of OPC: 1–1.4 h
•	 Maximum COMT inhibition: between 3.8 h and 7.7 h after the first OPC
•	 144 h after the last dose: 16.3%, 21.3%, 31.4% and 20.3% decrease in COMT activity 
(5 mg, 10 mg, 20 mg and 30 mg OPC, respectively)
Rocha et al36 Administration of 25 mg, 50 mg, and 
75 mg OPC or PLC for 11 days. in the 
12th day, subjects in the PLC group 
received 200 mg eNT + LD/CD tid. 
individuals in the OPC group were 
given LD/CD tid
•	 Minimum LD plasma concentration increased in all active treatment groups 
compared to PLC
•	 All active treatments increased LD bioavailability and significantly decreased 3-OMD 
exposure
•	 OPC showed a more sustained effect on erythrocyte COMT inhibition than eNT
Abbreviations: 3-OMD, 3-O-methyldopa; CD, carbidopa; COMT, catechol-O-methyltransferase; eNT, entacapone; LD, levodopa; OPC, opicapone; PLC, placebo; tid, three 
times a day.
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were administered once daily for 407 patients with PD 
showing end-of-dose motor fluctuations.40 The inclusion and 
exclusion criteria were similar to that of the BIPARK I study. 
Based on patients’ diaries, the reduction in the OFF time was 
significantly greater in both 25 mg and 50 mg OPC groups 
compared to PLC (1.7 h, 2.0 h and 1.1 h, respectively).The 
increase in the ON time with or without non-troublesome 
dyskinesia in both OPC groups was also greater than that in 
the PLC group (1.4 h, 1.43 h and 0.8 h in 25 mg and 50 mg 
OPC and PLC groups, respectively). OPC was found to be 
safe and well tolerated.40
Table 2 summarizes the main findings of clinical trials 
in PD patients.
Pooled analysis and extension 
studies
Pooled analyses of the BIPARK I and BIPARK II studies 
have been carried out. Currently, only abstracts are available. 
The double-blind phases of both studies were pooled and 
assessed for hepatobiliary adverse events.41 No clinically 
relevant changes were observed in hepatic enzyme levels. 
No cases of severe hepatotoxic events were reported.
It was found that OPC improved motor fluctuations 
regardless of concomitant DA agonist or MAO-B inhibitor 
therapy at baseline.42 Exploratory post hoc analysis showed 
that OPC improved motor fluctuations as early as in the first 
week of treatment (decreased the OFF time by 61 min and 
75 min with 25 mg and 50 mg OPC, respectively) and had 
maximum and sustained beneficial effects after 2–3 weeks.43 
It was also demonstrated that OPC treatment resulted in a 
significant improvement in motor fluctuations regardless of 
the baseline Hoehn–Yahr stage or disease duration.44 Patients 
older than 70 years also responded well to the OPC therapy.45 
The mean OFF time was reduced by 1.40 h, 1.77 h and 2.26 h 
with PLC, 25 mg and 50 mg OPC treatment, respectively. 
Hallucinations (4.6%) and weight loss (4.6%) were more 
common in this subpopulation of patients, but still, OPC was 
found to be safe and well tolerated.
One-year open-label extension studies for both BIPARK I 
and BIPARK II were performed. To date, data are available 
only as abstracts. All participants received 25 mg OPC for 
1 week, and then the investigators could freely adjust doses 
of both OPC (5 mg, 25 mg and 50 mg) and LD according 
to clinical response and safety concerns. After the double-
blind phase, 495 patients continued the BIPARK I study for 
1 year.46,47 The primary end point was the change in the OFF 
time based on patients’ diaries. In relation to the open-label 
extension baseline, the mean OFF time decreased by 34 min.48 
Participants who previously received PLC and ENT showed 
a statistically significant reduction in the OFF time (65 min 
Table 2 Summary of clinical trials in PD patients
References Design Main findings
Rocha et al37 25 mg, 50 mg and 100 mg OPC or PLC 
qd in addition to previous 100/25 mg 
LD and CD or BZ
•	 Maximum plasma concentration of LD dose dependently increased after OPC 
intake
•	 All active treatments inhibited the extent and rate of COMT activity
•	 Marked decrease in time to ON and time to best ON
•	 ON duration increased by 18% and 25% with 25 mg and 50 mg OPC, respectively
Ferreira 
et al38
28-day long administration of 5 mg, 
15 mg and 30 mg OPC
•	 All active treatments increased LD bioavailability in a dose-dependent manner
•	 All active treatments caused a decrease in absolute OFF time (15.6 min and 
145 min with 5 mg and 30 mg OPC, respectively)
•	 investigators’ and patients’ global assessment of change was favorable
Ferreira  
et al21  
(BiPARK i)
PLC, 200 mg eNT or 5 mg, 25 mg 
or 50 mg OPC for 14–15 weeks in 
addition to LD (administered three to 
eight times qd)
•	 Reduction in the OFF time for 50 mg OPC compared to PLC (−116.8 min  
and −56 min, respectively)
•	 5 mg and 25 mg of OPC did not show significant reduction in the time spent in the 
OFF state
•	 Higher proportion of patients showed at least 1 h reduction in the OFF state in the 
25 mg and 50 mg OPC groups
•	 Proportion of patients who had at least 1 h increase in the ON state was 
significantly higher in the 50 mg OPC arm
•	 OPC was superior to PLC and non-inferior to eNT
Lees et al40 
(BiPARK ii)
25 mg and 50 mg OPC qd •	 Reduction in the OFF time was significantly greater in both 25 mg and 50 mg OPC 
groups compared to PLC (1.7 h, 2.0 h and 1.1 h, respectively)
•	 increase in the ON time with or without non-troublesome dyskinesia in both OPC 
groups were greater than in the PLC group (1.4 h, 1.43 h and 0.8 h in 25 mg OPC, 
50 mg OPC and PLC groups, respectively)
Abbreviations: BZ, benserazide; CD, carbidopa; COMT, catechol-O-methyltransferase; eNT, entacapone; LD, levodopa; OPC, opicapone; qd, once daily; PD, Parkinson’s 
disease; PLC, placebo.
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and 39 min, respectively) and increase in the ON time without 
troublesome dyskinesia (43 min and 46 min, respectively) 
compared to the open-label baseline. Those who were initially 
receiving OPC had a sustained beneficial effect regarding 
both ON and OFF times. Unified Parkinson’s Disease Rating 
Scale (UPDRS) II scores in ON and OFF states and UPDRS 
III score at the end point of the open-label phase (−2.2, −4.4 
and −7.4 points, respectively) showed improvement com-
pared to previous PLC treatment.49 The most common adverse 
events in the extension study were related to dopaminergic 
effects: dyskinesia (14.5%), decrease in the effect of the 
medication (12.1%), and worsening of parkinsonism (6.7%).45 
A total of 11 deaths occurred during the trial; however, none 
was found to be related to OPC treatment.
A total of 367 patients participated in the 1-year open-
label extension of the BIPARK II trial.50 The primary end 
point was the change in the OFF time compared to baseline 
based on patients’ diaries. A marked reduction in the OFF 
time (~1.5 h) was observed compared to the open-label 
baseline for patients previously taking PLC. The OFF time 
reductions (12.5%), percentage of the OFF time responders 
(67.5%) and increase in the ON time with or without non-
troublesome dyskinesia (~1.7 h) were consistent with the 
results of the double-blind phase of the trial.50 The most 
common treatment-related adverse events were dyskinesia 
(21.5%), worsening symptoms of PD (17%), falls (9.1%), 
increased level of blood creatine phosphokinase (7.4%), 
insomnia (5.7%) and orthostatic hypotension (5.4%).51 
These adverse events were mild to moderate. A fatal intrac-
erebral hemorrhage occurred after traumatic brain injury 
in one of the participants. The other four deaths in the trial 
were unrelated to OPC treatment. One confirmed case of 
melanoma was reported, and 4% of subjects had impulse 
control disorders (ICDs). No effects of OPC on suicidality 
have been shown.51
Pooled analyses of the double-blind and open-label 
stages of BIPARK I and BIPARK II have been carried out. 
Currently, only abstracts are available. ICDs were detected 
in 1.5% of patients, the most common being pathological 
gambling. ICDs were mild to moderate in intensity.52 No 
increased risk for suicidality was found.
The results of both BIPARK I and II were pooled and 
analyzed for ECG abnormalities.53 A total of 3,060 ECGs 
were examined. Slight, albeit clinically irrelevant, increase in 
the QRS interval (1.6 ms and 0.9 ms with 25 mg and 50 mg 
OPC treatment, respectively) was observed.
Table 3 summarizes the results of extension studies and 
pooled analysis.
Discussion
OPC is a promising new peripheral COMT inhibitor that has 
been approved for adjunctive therapy to LD/DDCI in PD 
patients showing motor fluctuations. Preclinical and clinical 
studies have shown that OPC, compared to the previous two 
COMT inhibitors, is more efficacious, has a significantly 
longer effect and is less toxic. Therefore, if long-term results 
will show similar beneficial effects, it should become the first-
choice COMT inhibitor. Although ENT is a safe medication, 
its efficacy is limited and requires frequent administration.54 
Table 3 Summary of extension studies and pooled analyses of 
BiPARK i and BiPARK ii
References Results
Lopes et al41 •	 No clinically relevant changes in hepatic enzyme 
levels
•	 No cases of severe hepatotoxic events
Lopes et al42 •	 OPC improved motor fluctuations regardless of 
baseline DA agonist or MAO-B inhibitor therapy
Lees et al43 •	 OPC improved motor fluctuations by the first week 
of treatment and had maximum and sustained effects 
after 2–3 weeks
Lopes et al44 •	 OPC therapy improved motor fluctuations regardless 
of the baseline Hoehn–Yahr stage or disease duration
Lees et al45 •	 Patients aged .70 years responded well to OPC 
therapy
Ferreira et al48 •	 Patients taking PLC or eNT showed statistically 
significant reduction in the OFF time and increase in 
the ON time without troublesome dyskinesia after 
switching to OPC
•	 Patients initially on OPC therapy had a sustained 
beneficial effect regarding both ON and OFF times
Ferreira et al49 •	 UPDRS ii scores in the ON and OFF states, and 
UPDRS iii score showed improvement compared  
to previous PLC treatment
Santos et al61 •	 Most common adverse events were dyskinesia, 
decrease in the effect of the medication and 
worsening of parkinsonism 
Costa et al50 •	 Marked reduction in the OFF time was observed 
compared to the open-label baseline for patients 
previously taking PLC
•	 OFF time reduction and increase in the ON time 
with or without non-troublesome dyskinesia were 
detected
Lees et al51 •	 Treatment-related adverse events were dyskinesia, 
worsening symptoms of PD, falls, increased level 
of blood creatine phosphokinase, insomnia and 
orthostatic hypotension
Lopes et al52 •	 iCDs were detected in 1.5% of patients
•	 One confirmed case of melanoma
•	 4.0% of subjects had iCDs
Pinto et al53 •	 Clinically irrelevant increase in the QRS interval was 
observed
Abbreviations: DA, dopamine; eNT, entacapone; iCD, impulse control disorder; 
MAO-B, monoamine oxidase B; OPC, opicapone; PD, Parkinson’s disease; 
PLC, placebo; UPDRS, Unified Parkinson’s Disease Rating Scale.
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TCP compared to ENT is more efficacious and has a more 
sustained effect on COMT activity. However, its safety profile is 
unfavorable. Three cases of fatal hepatotoxicity were previously 
reported.55–57 Owing to its hepatotoxic effect, the administration 
of TCP requires frequent liver function monitoring and there-
fore it is only recommended to a few selected patients among 
those showing motor fluctuations and poor motor control.58
The recommended dose for OPC is 50 mg once daily 
taken at bedtime at least 1 h before or after intake of LD 
therapy.59 Since it has .24 h long COMT inhibitory effect, 
it can be expected that coadministration of this novel drug to 
LD/DDCI medications will result in better control of motor 
and maybe even nonmotor symptoms of PD patients. It is 
also possible that the required doses for LD/DDCI medica-
tions can be reduced due to the sustained effects of OPC and 
should allow for better compliance from the patients.
OPC therapy is thus far only recommended for patients 
who have been taking LD therapy for years and are inevitably 
showing signs of motor fluctuations. In the future, it would 
be interesting to see the effects of OPC treatment before the 
occurrence of motor fluctuations. In the STRIDE-PD study, 
early initiation of ENT treatment in addition to LD/CD did not 
delay the occurrence of dyskinesia compared to LD/CD alone.60 
In fact, the time of onset of dyskinesia was shorter and the fre-
quency of dyskinesia was increased in the LD/CD/ENT group 
compared to the LD/CD arm. The authors hypothesized that 
these findings were probably due to higher LD dose equivalents 
in the first group and that continuous dopaminergic stimulation 
was not achieved. Still, we believe that there is a possibility that 
OPC can delay the onset of the adverse effects of LD therapy by 
providing steadier and continuous plasma LD concentrations.
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